Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Trial details
- Registry ID
- NCT05954143
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerNCT05954143 | BOLT | Phase 2 | Terminated | 2024-09-20Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |